Loading...
Market
Next major action by Novavax on halted trials by March 31, 2025?
2
Resolution / Starting Odds
Resume trials • 25%
Modify trial protocols • 25%
Abandon trials • 25%
Seek alternative partnerships • 25%
Novavax press releases and corporate announcements
Story
Novavax (NVAX) Shares Plunge 20% as FDA Halts Phase 3 COVID-Flu Vaccine Trials Over Motor Neuropathy
Oct 16, 2024, 02:17 PM
Novavax (NASDAQ: NVAX) announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Investigational New Drug (IND) applications for both its COVID-19-influenza combination vaccine and its stand-alone influenza vaccine candidates in Phase 3 trials. The hold is due to safety concerns following a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a trial participant. Following the news on Wednesday, shares of Novavax plunged by up to 20%, with the stock dropping as much as 18.7% during trading.
View original story
Similar markets
Yes • 50%
No • 50%
Partnership with another company • 25%
Focus on different vaccine candidates • 25%
Continue with current strategy • 25%
Other strategic response • 25%
Attributed to vaccine • 25%
Attributed to unrelated causes • 25%
Inconclusive • 25%
No further information released • 25%
Safety concerns resolved • 25%
Further investigation required • 25%
Vaccine trials permanently halted • 25%
Other outcome • 25%
Hold lifted with no conditions • 25%
Hold lifted with conditions • 25%
Hold extended • 25%
Hold converted to permanent suspension • 25%
Increases by 10% or more • 25%
Decreases by 10% or more • 25%
Remains within 10% of current value • 25%
Other outcome • 25%
Successful with no major side effects • 25%
Successful with some side effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
Yes • 50%
No • 50%
